Board member
Infectious Diseases
LEO Pharma
Denmark
Mrs. Ingelise Saunders, Mph, B.Sc. serves as the Chief Executive Officer of SLS Invest. Mrs. Saunders has been Chief Executive Officer of TD Vaccines A/S since November 2009 and serves as its President. She served as Chief Executive Officer of Action Pharma A/S since March 2010. She served as the Chief Executive Officer at Celltech Pharmaceuticals at Celltech Group Limited since March 2002. She served as Chief Executive Officer of UCB Pharma Ltd. Mrs. Saunders served as Global Commercial Director of Celltech Group Limited. Mrs. Saunders joined Celltech Group PLC in September 2001 as a Director of European Pharmaceutical Operations, with overall responsibility for the management of the European operating companies and development of organizational capabilities within Europe. She has over 30 years experience in the pharmaceutical industry. Following the acquisition of Celltech by UCB, Mrs. Saunders returned to Denmark after seven years in the United Kingdom, served as Chief Executive Officer at ACE BioSciences A/S. She started her career as a Medical Representative then a Sales Manager at Ferrosan Holding A/S, followed by positions as the Sales Manager at Schering-Plough Corporation and Marketing Director at Glaxo A/S. Mrs. Saunders joined Novo Farmaka A/S in Denmark in 1986 as a General Manager. In 1992, she was transferred to Novo Nordisk A/S head office as the Vice President of International Operations, with overall responsibility for the Nordic area and Benelux countries. Mrs. Saunders has moved throughout Novo Nordisk, working in Business Development, Health Care Strategy and becoming the President of the Pharmaceuticals Division. Her last position at Novo was as a Managing Director, Ireland and the United Kingdom and Vice President of Novo Nordisk Europe, this involved restructuring the United Kingdom and Ireland business area and introducing a more business focused culture. Mrs. Saunders serves as a Director at LEO Pharma A/S, Scandinavian Life Science Venture III AB, TD Vaccines A/S and Gyros AB. She serves as the Chairman of the Board of Directors at Avilex Pharma Aps. She serves as a Member of the Board at Ecron Acunova A/S. She holds Board positions at NsGene A/S and AdvanDx. She serves as a Member of Advisory Board at Quester Venture Partnership, L.P. She serves as Director of SLS Invest. She served as an Independent Board Member of Topotarget A/S since September 2004. She served as an Executive Director of Celltech Group Limited from October 22, 2003 to July 2004. She served as a Director of ALK-Abelló A/S since 2005 and Evolva Holding SA. since December 2009. Mrs. Saunders has a Master degree in Pharmacy from the University of Copenhagen and a Bachelor of Commerce degree in Marketing.
Infectious Disease